Haleos
1,315.10
-41.40(-3.05%)
Market Cap₹- Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D-3.05%
1M+11.36%
6M+0.40%
1Y+12.79%
5Y+100.00%
View Company Insightsright
More news about Haleos
11Aug 25
SMS Lifesciences India Reports Q1 Results, Schedules AGM
SMS Lifesciences India Limited, an API manufacturer, reported a decline in Q1 financial results. Revenue from operations decreased by 8.70% to Rs. 7,904.27 lakhs, while net profit fell by 20.16% to Rs. 515.77 lakhs compared to the previous year. The company's EPS dropped to Rs. 17.06 from Rs. 21.37. On a consolidated basis, revenue from operations was Rs. 8,250.46 lakhs, with a net profit of Rs. 438.21 lakhs. The Board approved Q1 results, scheduled the AGM for September 30, and approved various company policies.
01Aug 25
SMS Lifesciences India Shareholders Approve Six Resolutions, Including Name Change and Executive Reappointment
SMS Lifesciences India Limited announced the results of its postal ballot, with shareholders overwhelmingly approving six resolutions. These include changing the company name, reappointing Mr. TV Praveen as Executive Director, increasing individual and overall managerial remuneration limits, and approving material related party transactions for the company and its material subsidiary. The voting, conducted from July 1 to July 30, 2025, saw most resolutions receiving over 99% approval. The resolutions are deemed passed as of July 30, 2025, signaling potential strategic changes for the company.
16Jul 25
SMS Lifesciences Receives VAI Status from USFDA for API Facility in Telangana
SMS Lifesciences India Limited has received Voluntary Action Indicated (VAI) status from the USFDA for its API manufacturing facility in Kazipally, Telangana. The Establishment Inspection Report with VAI status was received on July 15, 2025. This status indicates general compliance with good manufacturing practices, with minor issues to be addressed. The VAI classification allows the facility to continue operations and export products to the US without significant regulatory hurdles. Company Secretary Trupti Ranjan Mohanty stated that this reaffirms their commitment to global quality standards and enables access to regulated markets.
14Jul 25
SMS Lifesciences Unveils ₹145 Crore Investment Plan to Boost Specialized API Production
SMS Lifesciences India Limited plans to invest ₹145 crore to expand production of specialized Active Pharmaceutical Ingredients (APIs). The company aims for global sector leadership by FY 2028 through backward integration and USFDA-compliant manufacturing. Recent financial highlights include a 12.67% increase in consolidated revenue to ₹344.72 crore and a 196.04% rise in PAT to ₹18.73 crore for FY 2025. The company plans to expand its product portfolio to over 50 products by FY 2028. Recent regulatory achievements include successful USFDA audits of its manufacturing plants. SMS Lifesciences continues to invest in R&D, spending ₹6.30 crore in FY 2025 and filing seven Drug Master Files with the USFDA.
29May 25
SMS Lifesciences India Reports Decline in Q4 Profit
SMS Lifesciences India's Q4 financial results show a significant decline in net profit to ₹30.00 crore, down 49% from ₹59.00 crore in the previous year. Revenue remained relatively stable at ₹891.00 crore, a slight 1% decrease from ₹900.00 crore. The stark contrast between steady revenue and falling profits suggests potential increases in operational costs or other factors affecting profitability in the pharmaceutical sector.
09May 25
SMS Lifesciences India's API Facility Inspection by USFDA Concludes with One Observation
SMS Lifesciences India Limited's Active Pharmaceutical Ingredient (API) manufacturing facility in Telangana underwent a USFDA inspection, concluding with only one observation. This outcome indicates strong regulatory compliance and could boost market confidence and export potential for the company. The management is expected to address the single observation promptly, reinforcing their commitment to maintaining high-quality standards in API manufacturing.
Haleos
1,315.10
-41.40
(-3.05%)
1 Year Returns:+12.79%
Industry Peers
Windlas Biotech
790.15
(+0.55%)
Jeena Sikho Lifecare
699.20
(+0.52%)
Blue Jet Healthcare
554.80
(-2.56%)
Abbott
28,850.00
(-0.14%)
Sunrest Lifescience
42.05
(-2.21%)
Zenith Drugs
54.60
(+2.25%)
Pfizer
5,001.00
(+0.57%)
FDC
414.10
(+0.24%)